AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

The pharmaceutical company hopes that another big-time acquisition will pay off.

CryptoAlerta — análise de criptomoedas e mercado em tempo real